2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

osine kinases that can lead to activation of both the
mitogen-activated protein kinase (MAPK) and PI3K pathways,
such as the insulin-like growth factor 1 receptor
(IGF-1R) and MET pathways, represents an attractive strategy
to reverse EGFR resistance and is actively being investigated
in the clinical setting. 18,19 In addition, phase I trials
combining inhibitors of the MAPK pathway (such as RAF or
MEK) and PI3K pathway (such as PI3K, AKT, or mammalian
target of rapamycin [mTOR]) are near completion and
would be of interest in SCCHN, especially among patients
whose tumors harbor molecular aberrations in these key
signaling cascades.
Authors’ Disclosures of Potential Conflicts of Interest
Author
Employment or
Leadership
Positions
Consultant or
Advisory Role
Conclusion
Emerging innovations in surgical, radiation, and medical
oncology aim to improve technical precision and molecular
targeting in disease management for patients with SCCHN.
Clinical trial evaluations are needed to translate these early
advances into practice. Ultimately, the goal of these
precision-based strategies is to optimize disease control with
increased technical and scientific targeting while sparing
healthy tissue toxicity and late effects, such that translation
to tangible clinical benefits in patients with SCCHN is
achieved.
Stock
Ownership Honoraria
Research
Funding
Eric Bissada*
Irene Brana*
Lillian L. Siu Amgen EntreMed (I) Abraxis
BioScience;
Bristol-Myers
Squibb;
Genentech;
GlaxoSmithKline;
Merck;
Millennium;
Novartis; Pfizer;
Regeneron;
Roche
*No relevant relationships to disclose.
1. Iseli TA, Kulbersh BD, Iseli CE, et al. Functional outcomes after
transoral robotic surgery for head and neck cancer. Otolaryngol Head Neck
Surg. 2009;141:166-171.
2. Genden EM, Desai S, Sung CK. Transoral robotic surgery for the
management of head and neck cancer: a preliminary experience. Head Neck.
2009;31:283-289.
3. Cosmidis A, Rame JP, Dassonville O, et al. T1-T2 NO oropharyngeal
cancers treated with surgery alone: a GETTEC study. Eur Arch Otorhinolaryngol.
2004;261:276-281.
4. Allal AS, Nicoucar K, Mach N, et al. Quality of life in patients with
oropharynx carcinomas: assessment after accelerated radiotherapy with or
without chemotherapy versus radical surgery and postoperative radiotherapy.
Head Neck 2003;25:833-839.
5. Moncrieff M, Sandilla J, Clark J, et al. Outcomes of primary surgical
treatment of T1 and T2 carcinomas of the oropharynx. Laryngoscope. 2009;
119:307-311.
6. Weinstein GS, O’Malley BW Jr, Snyder W, et al. Transoral robotic
surgery: radical tonsillectomy. Arch Otolaryngol Head Neck Surg. 2007;133:
1220-1226.
7. Weinstein GS, Quon H, O’Malley BW Jr, et al. Selective neck dissection
and deintensified postoperative radiation and chemotherapy for oropharyngeal
cancer: a subset analysis of the University of Pennsylvania transoral
robotic surgery trial. Laryngoscope 2010;120:1749-1755.
8. Ramaekers BL, Pijls-Johannesma M, Joore MA, et al. Systematic review
and meta-analysis of radiotherapy in various head and neck cancers: comparing
photons, carbon-ions and protons. Cancer Treat Rev. 2011;37:185-201.
9. Sok JC, Coppelli FM, Thomas SM, et al. Mutant epidermal growth factor
receptor (EGFRvIII) contributes to head and neck cancer growth and resistance
to EGFR targeting. Clin Cancer Res. 2006;12:5064-5073.
10. Seiwert TY, Fayette J, Del Campo JM, et al. Updated results of a
randomized, open-label phase II study exploring BIBW 2992 versus cetux-
376
REFERENCES
BISSADA, BRANA, AND SIU
Expert
Testimony
Other
Remuneration
imab in patients with platinum-refractory metastatic/recurrent head and
neck cancer (SCCHN). Ann Oncol 2010;21:viii316 (abstr 1010PD).
11. Siu LL, Hotte SJ, Laurie SA, et al. Phase II trial of the irreversible oral
pan-human EGF receptor (HER) inhibitor PF-00299804 (PF) as first-line
treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of
the head and neck (SCCHN). J Clin Oncol. 2011;29:45S (suppl; abstr 5561).
12. Jura N, Endres NF, Engel K, et al. Mechanism for activation of the EGF
receptor catalytic domain by the juxtamembrane segment. Cell. 2009;137:
1293-1307.
13. Soltoff SP, Carraway KL III, Prigent SA, et al. ErbB3 is involved in
activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol
Cell Biol. 1994;14:3550-3558.
14. Prigent SA, Gullick WJ. Identification of c-erbB-3 binding sites for
phosphatidylinositol 3�-kinase and SHC using an EGF receptor/c-erbB-3
chimera. EMBO J. 1994;13:2831-2841.
15. Schaefer G, Haber L, Crocker LM, et al. A two-in-one antibody against
HER3 and EGFR has superior inhibitory activity compared with monospecific
antibodies. Cancer Cell. 2011;20:472-486.
16. Takikita M, Xie R, Chung JY, et al. Membranous expression of Her3 is
associated with a decreased survival in head and neck squamous cell
carcinoma. J Transl Med. 2011;9:126.
17. Wilson TR, Lee DY, Berry L, et al. Neuregulin-1-mediated autocrine
signaling underlies sensitivity to HER2 kinase inhibitors in a subset of
human cancers. Cancer Cell. 2011;20:158-172.
18. Wheeler DL, Huang S, Kruser TJ, et al. Mechanisms of acquired
resistance to cetuximab: role of HER (ErbB) family members. Oncogene.
2008;27:3944-3956.
19. Jameson MJ, Beckler AD, Taniguchi LE, et al. Activation of the
insulin-like growth factor-1 receptor induces resistance to epidermal growth
factor receptor antagonism in head and neck squamous carcinoma cells. Mol
Cancer Ther. 2011;10:2124-2134.